*CG Power & Industrial Solutions Ltd.* | *CMP* Rs. 82 | *M Cap* Rs. 10972 Cr | *52 W H/L* 92/5
(Nirmal Bang Retail Research)
*Result improved*
Revenue from Operations came at Rs. 1117.8 Cr (36.4% QoQ, 81.4% YoY) vs QoQ Rs. 819.5 Cr, YoY Rs. 616.3 Cr
EBIDTA came at Rs. 114.5 Cr (18.6% QoQ, -237.2% YoY) vs QoQ Rs. 96.6 Cr, YoY Rs. -83.5 Cr (EbITDA for Q4 is adjusted for Rs.46cr legacy one off expenses accounted during the quarter)
EBITDA Margin came at 10.2% vs QoQ 11.8%, YoY -13.5%
Adj. PAT came at Rs. 64 Cr vs QoQ Rs. 481.8 Cr, YoY Rs. -115.2 Cr (lot of variation in PAT is on account of Exceptional in all the quarter)
Quarter EPS is Rs. 0.5
(Nirmal Bang Retail Research)
*Result improved*
Revenue from Operations came at Rs. 1117.8 Cr (36.4% QoQ, 81.4% YoY) vs QoQ Rs. 819.5 Cr, YoY Rs. 616.3 Cr
EBIDTA came at Rs. 114.5 Cr (18.6% QoQ, -237.2% YoY) vs QoQ Rs. 96.6 Cr, YoY Rs. -83.5 Cr (EbITDA for Q4 is adjusted for Rs.46cr legacy one off expenses accounted during the quarter)
EBITDA Margin came at 10.2% vs QoQ 11.8%, YoY -13.5%
Adj. PAT came at Rs. 64 Cr vs QoQ Rs. 481.8 Cr, YoY Rs. -115.2 Cr (lot of variation in PAT is on account of Exceptional in all the quarter)
Quarter EPS is Rs. 0.5
*DLF LTD.* | *CMP* Rs. 310 | *M Cap* Rs. 76735 Cr | *52 W H/L* 333/130
(Nirmal Bang Retail Research)
Sales Booking came at Rs.1058cr vs QoQ Rs.1022cr YoY Rs.325cr
*Result ok*
Revenue from Operations came at Rs. 1712.6 Cr (11% QoQ, 1.1% YoY) vs QoQ Rs. 1543 Cr, YoY Rs. 1694.2 Cr
EBIDTA came at Rs. 453.9 Cr (-9.1% QoQ, 43.3% YoY) vs QoQ Rs. 499.1 Cr, YoY Rs. 316.7 Cr
EBITDA Margin came at 26.5% vs QoQ 32.3%, YoY 18.7%
Adj. PAT came at Rs. 480.9 Cr vs QoQ Rs. 451.2 Cr, YoY Rs. -1527.1 Cr
Quarter EPS is Rs. 1.9
Share is trading at P/E of 48.5x FY22E EPS
(Nirmal Bang Retail Research)
Sales Booking came at Rs.1058cr vs QoQ Rs.1022cr YoY Rs.325cr
*Result ok*
Revenue from Operations came at Rs. 1712.6 Cr (11% QoQ, 1.1% YoY) vs QoQ Rs. 1543 Cr, YoY Rs. 1694.2 Cr
EBIDTA came at Rs. 453.9 Cr (-9.1% QoQ, 43.3% YoY) vs QoQ Rs. 499.1 Cr, YoY Rs. 316.7 Cr
EBITDA Margin came at 26.5% vs QoQ 32.3%, YoY 18.7%
Adj. PAT came at Rs. 480.9 Cr vs QoQ Rs. 451.2 Cr, YoY Rs. -1527.1 Cr
Quarter EPS is Rs. 1.9
Share is trading at P/E of 48.5x FY22E EPS
Indian jewellers lift shutters; discounts prevail in top hubs
https://www.livemint.com/market/commodities/indian-jewellers-lift-shutters-discounts-prevail-in-top-hubs-11623455997384.html
India's gold imports in May surged over nine-fold from 2020's low base to 12 tonnes.
https://www.livemint.com/market/commodities/indian-jewellers-lift-shutters-discounts-prevail-in-top-hubs-11623455997384.html
India's gold imports in May surged over nine-fold from 2020's low base to 12 tonnes.
mint
Indian jewellers lift shutters; discounts prevail in top hubs
India's gold imports in May surged over nine-fold from 2020's low base to 12 tonnes.
EKC One of the biggest suppliers of oxygen cylinders in the country has been blacklisted for two years by the Union health ministry for failure to deliver orders on time and its ‘non commitment to the national cause’ amid the pandemic. Pls inform all your followers to sell it and run away from EVEREST Kanto Cylinders
Read more at:
https://economictimes.indiatimes.com/news/india/key-o2-cylinder-provider-blacklisted-for-supply-failure/articleshow/83443667.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Read more at:
https://economictimes.indiatimes.com/news/india/key-o2-cylinder-provider-blacklisted-for-supply-failure/articleshow/83443667.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
The Economic Times
Key O2 cylinder provider blacklisted for supply failure
On May 24, the Central Medical Services Society (CMSS) –– the health ministrys procurement agency for health goods –– cancelled an order for 44,000 oxygen cylinders and blacklisted Everest Kanto Cylinders (EKC) Ltd –– for two years.
Iron ore price correction delayed as global steel demand tops 2bn tonnes for first time ever - MINING.COM
https://www.mining.com/iron-ore-price-correction-delayed-as-global-steel-demand-tops-2bn-tonnes-first-time-ever/
https://www.mining.com/iron-ore-price-correction-delayed-as-global-steel-demand-tops-2bn-tonnes-first-time-ever/
MINING.COM
Iron ore price correction delayed as global steel demand tops 2bn tonnes for first time ever
New report says China’s green push means end of cheap exports, deflating steel prices in rest of the world supporting iron ore prices.
Zydus Cadila has received tentative approval from the USFDA to market Osimertinib Tablets in the strengths of 40 mg and 80 mg (US RLD: Tagrisso Tablets).
Osimertinib is used to treat lung cancer. It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement o
One more positive news
Osimertinib is used to treat lung cancer. It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement o
One more positive news
*How to create more Wealth through Share Market..?*
Many of us know Warren Buffett, the most successful investor in the world. He is a value investor. He learned value investing from Benjamin Graham. Graham is considered the father of Value Investing.
Buffett started his investment as a value investor as taught by Graham. However, over time, he has modified that approach and become more successful.
Graham buys an undervalued stock and sells it at a fair price. This is a " Buy low and sell high"strategy. It is a quantitative approach. You do not need to know anything about the company except for its numbers. You see good profit, low valuation, good financial condition, you can buy it without even knowing what the company does. It is very easy and quick. With good diversification and margin of safety, you can easily beat the market.
Buffett followed this quantitative approach but he found that soon after he sold the stocks, certain stocks tend to get higher. He found that the company with "Moat"continues to rise.
He is influenced by another great investor, Fisher. Fisher recommends a " Buy & Hold" strategy.
Buffett merges these two strategies and created his unique style.
He selects companies based on qualitative analysis with a good "Moat". These companies possess a " Durable Competitive Advantage" over their competitors. But he buys only when it is available at an undervaluation. He holds the company for a long time.
Buffett is 85% Graham and 15% Fisher.
*Happy Investing !!!*
Many of us know Warren Buffett, the most successful investor in the world. He is a value investor. He learned value investing from Benjamin Graham. Graham is considered the father of Value Investing.
Buffett started his investment as a value investor as taught by Graham. However, over time, he has modified that approach and become more successful.
Graham buys an undervalued stock and sells it at a fair price. This is a " Buy low and sell high"strategy. It is a quantitative approach. You do not need to know anything about the company except for its numbers. You see good profit, low valuation, good financial condition, you can buy it without even knowing what the company does. It is very easy and quick. With good diversification and margin of safety, you can easily beat the market.
Buffett followed this quantitative approach but he found that soon after he sold the stocks, certain stocks tend to get higher. He found that the company with "Moat"continues to rise.
He is influenced by another great investor, Fisher. Fisher recommends a " Buy & Hold" strategy.
Buffett merges these two strategies and created his unique style.
He selects companies based on qualitative analysis with a good "Moat". These companies possess a " Durable Competitive Advantage" over their competitors. But he buys only when it is available at an undervaluation. He holds the company for a long time.
Buffett is 85% Graham and 15% Fisher.
*Happy Investing !!!*
Sun TV – First Cut – Ebitda and Ad revenue beat estimates
· Q4 Net Profit Rs450cr (up 80% YoY) - Estimate Rs425cr
· Revenue Rs782cr (up 6.4% YoY) - Estimate Rs812.2cr
· Other income Rs50.59cr (down 11% YoY) – Estimates Rs57.7cr
· Ebitda Rs547cr (up 8.5% YoY) - estimate 561cr
· Q4 Subscription revenue Rs428cr
· 4Q Advertisement Revenue Rs315cr (up 8% YoY) – expectation flat growth
· Q4 Net Profit Rs450cr (up 80% YoY) - Estimate Rs425cr
· Revenue Rs782cr (up 6.4% YoY) - Estimate Rs812.2cr
· Other income Rs50.59cr (down 11% YoY) – Estimates Rs57.7cr
· Ebitda Rs547cr (up 8.5% YoY) - estimate 561cr
· Q4 Subscription revenue Rs428cr
· 4Q Advertisement Revenue Rs315cr (up 8% YoY) – expectation flat growth
BEML:
Q4 SL NET PROFIT 1.60B RUPEES VS 1.86B (YOY); EST 1.5B | 293M (QOQ)
Q4 REVENUE 17.74B RUPEES VS 10.66B (YOY)
CO BOARD RECOMMENDED A FINAL DIVIDEND OF 1.20 RUPEES PER SHARE
Q4 SL NET PROFIT 1.60B RUPEES VS 1.86B (YOY); EST 1.5B | 293M (QOQ)
Q4 REVENUE 17.74B RUPEES VS 10.66B (YOY)
CO BOARD RECOMMENDED A FINAL DIVIDEND OF 1.20 RUPEES PER SHARE
Centuryply concall
MDF:
150000 CBM we did in FY21 vs our capacity of 180000 CBM. We cant match demand since it is very high but we have room to grow.
Q - MDF cannibalize Plywood?
A - Not at all. There is a segment for each of our products. We had the same thought but now we are sure and hence we are going all in on MDF.
Q - Impact of Imports?
A - We are not worried. At least for next 18 months as there is enough demand. We are also in talk with Govt. ADD might come in.
Q - MDF margin at 27%. Is there room for leverage?
A - Not expecting higher margins. We can maintain it.
Both Plywood and MDF, unorganized are taking a bigger hit cos of RM procurement and working capital.
We want to triple our MDF share. Which is visible in our investments. Between 2015 to 2022, of the total cumulative capex of 1200 Cr, 575 Cr was in MDF. The final MDF expansion will come online in FY23.
Q – You have 180000 CBM in MDF. Rushil has added capacity. Greenpanel added last year. What is the scenario in India?
A – India total capacity is 1.5 Mn CBM. If you add ours and Rushil expansion, it will be 2Mn CBM. To give a perspective, 50 Mn CBM plus is China capacity. We have a long way to go.
Plywood:
Our run rate has been 1250 Cr. FY22, we had planned to do 1500 Cr through some capex and outsourcing by Q1 has been impacted. Long term, we can do 2000 Cr when all the capex is over. At 13.5 to 14% margins. We are bullish because of the growth in the last 2 quarters
MDF:
150000 CBM we did in FY21 vs our capacity of 180000 CBM. We cant match demand since it is very high but we have room to grow.
Q - MDF cannibalize Plywood?
A - Not at all. There is a segment for each of our products. We had the same thought but now we are sure and hence we are going all in on MDF.
Q - Impact of Imports?
A - We are not worried. At least for next 18 months as there is enough demand. We are also in talk with Govt. ADD might come in.
Q - MDF margin at 27%. Is there room for leverage?
A - Not expecting higher margins. We can maintain it.
Both Plywood and MDF, unorganized are taking a bigger hit cos of RM procurement and working capital.
We want to triple our MDF share. Which is visible in our investments. Between 2015 to 2022, of the total cumulative capex of 1200 Cr, 575 Cr was in MDF. The final MDF expansion will come online in FY23.
Q – You have 180000 CBM in MDF. Rushil has added capacity. Greenpanel added last year. What is the scenario in India?
A – India total capacity is 1.5 Mn CBM. If you add ours and Rushil expansion, it will be 2Mn CBM. To give a perspective, 50 Mn CBM plus is China capacity. We have a long way to go.
Plywood:
Our run rate has been 1250 Cr. FY22, we had planned to do 1500 Cr through some capex and outsourcing by Q1 has been impacted. Long term, we can do 2000 Cr when all the capex is over. At 13.5 to 14% margins. We are bullish because of the growth in the last 2 quarters
Marksans has announced that one of the world's largest pharma funds Orbimed is picking up10.7% stake of Rs 365 cr. Also, funds to be used for growth as it is a zero debt co. Positive
Heranba Ind Q4
➡️Profit up 64.3% at Rs 43.2 cr Vs Rs 26.3 cr
➡️Revenue up 25.3% at Rs 267.8 cr Vs Rs 213.7 cr
➡️EBITDA at Rs 57.6 cr Vs Rs 25.5 cr
➡️EBITDA margin at 21.5% Vs 11.9%
➡️Profit up 64.3% at Rs 43.2 cr Vs Rs 26.3 cr
➡️Revenue up 25.3% at Rs 267.8 cr Vs Rs 213.7 cr
➡️EBITDA at Rs 57.6 cr Vs Rs 25.5 cr
➡️EBITDA margin at 21.5% Vs 11.9%
Kedaara Capital-backed Vijaya Diagnostics files for listing
Private equity firm Kedaara Capital-backed diagnostic chain Vijaya Diagnostic Centre Ltd has filed the draft red herring prospectus for its initial public offering (IPO) in a move aimed at giving Kedaara a partial exit from its five-year-old investment. The IPO is a pure offer for sale of 35.68 million shares by the promoters of the company and Kedaara Capital. The IPO will see the investor and promoters collectively dilute a 35% stake in the company, with Kedaara alone diluting 30%. Investment banks ICICI Securities, Edelweiss and Kotak Mahindra Capital are advising the company on its IPO.
Vijaya Diagnostic offers pathology and radiology testing services through an extensive network, which consists of 80 diagnostic centres and 11 reference laboratories across 13 cities and towns in Telangana, Andhra Pradesh and in the National Capital Region and Kolkata. For the fiscal years 2021, 2020 and 2019, the company reported a revenue of INR 388.5 crore, INR 354.1 crore and INR 302.9 crore, respectively. It reported a profit of INR 84.9 crore, INR 62.5 crore and INR 46.2 crore, for the respective financial years.
Kedaara Capital had picked up a 40% stake in the diagnostic chain in 2016 for over INR 400 crore.
Private equity firm Kedaara Capital-backed diagnostic chain Vijaya Diagnostic Centre Ltd has filed the draft red herring prospectus for its initial public offering (IPO) in a move aimed at giving Kedaara a partial exit from its five-year-old investment. The IPO is a pure offer for sale of 35.68 million shares by the promoters of the company and Kedaara Capital. The IPO will see the investor and promoters collectively dilute a 35% stake in the company, with Kedaara alone diluting 30%. Investment banks ICICI Securities, Edelweiss and Kotak Mahindra Capital are advising the company on its IPO.
Vijaya Diagnostic offers pathology and radiology testing services through an extensive network, which consists of 80 diagnostic centres and 11 reference laboratories across 13 cities and towns in Telangana, Andhra Pradesh and in the National Capital Region and Kolkata. For the fiscal years 2021, 2020 and 2019, the company reported a revenue of INR 388.5 crore, INR 354.1 crore and INR 302.9 crore, respectively. It reported a profit of INR 84.9 crore, INR 62.5 crore and INR 46.2 crore, for the respective financial years.
Kedaara Capital had picked up a 40% stake in the diagnostic chain in 2016 for over INR 400 crore.
Affle to acquire Irish mobile marketing firm Jampp for $41-M
Mumbai-based, publicly listed Affle (India) Ltd, through its subsidiaries, has acquired Dublin, Ireland-based Jampp, a programmatic mobile marketing company, for USD 41.3 million in cash, including a contingent incremental consideration of USD 15 million to be paid over 3 years. Affle will pick up 100% equity and tech IP assets ownership in Jampp.
Jampp is a global platform that started in 2013 in Latin America and its largest teams continue to be based there. Its programmatic mobile advertising platform is used by app marketers to acquire new users and also to drive repeat usage and transactions with existing users. Jampp had unaudited consolidated revenue of USD 29.5 million in calendar 2020.
Mumbai-based, publicly listed Affle (India) Ltd, through its subsidiaries, has acquired Dublin, Ireland-based Jampp, a programmatic mobile marketing company, for USD 41.3 million in cash, including a contingent incremental consideration of USD 15 million to be paid over 3 years. Affle will pick up 100% equity and tech IP assets ownership in Jampp.
Jampp is a global platform that started in 2013 in Latin America and its largest teams continue to be based there. Its programmatic mobile advertising platform is used by app marketers to acquire new users and also to drive repeat usage and transactions with existing users. Jampp had unaudited consolidated revenue of USD 29.5 million in calendar 2020.
Godrej Fund buys Bangalore land parcel from Puravankara for Rs.700-Cr
Godrej Fund Management, the real estate-focused private equity arm of the Mumbai-based, publicly listed Godrej Properties, has bought a land parcel, with 1 million sq ft of development potential, in Bengaluru Urban from Bangalore-based, publicly-listed real estate developer Puravankara for around INR 700 crore. The deal includes an upfront payment of around INR 525 crore. The rest will be paid before the end of this year.
Godrej Fund Management, the real estate-focused private equity arm of the Mumbai-based, publicly listed Godrej Properties, has bought a land parcel, with 1 million sq ft of development potential, in Bengaluru Urban from Bangalore-based, publicly-listed real estate developer Puravankara for around INR 700 crore. The deal includes an upfront payment of around INR 525 crore. The rest will be paid before the end of this year.
*Dhfl to delist from Monday*.
45,000 crs lost by banks as amt written off.
FD holders lost 5,000 crs
Equity share holders lost 15,000 crs Mcap.
Yet not even a single bank official or KMP is in 'Jail'. THIS IS A FORWARD
45,000 crs lost by banks as amt written off.
FD holders lost 5,000 crs
Equity share holders lost 15,000 crs Mcap.
Yet not even a single bank official or KMP is in 'Jail'. THIS IS A FORWARD